AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05006833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Provider Training - Benefits Approach
Description: At each clinic randomized to benefits training, providers will be invited to participate in one, in-clinic, group-based training . Each training will last one-hour and providers will receive continuing medical education (CME) credit for participating. Trainings will focus on providers presenting the HPV vaccine as safe, best if received at 11- to 12-years of age, and prevents cancer.
Study NCT06113016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06113016 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05777863 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention
Description: A multidomain lifestyle intervention including the following lifestyle domains: (1) diet, (2) physical activity, (3) sleep, (4) stress/mindfulness, and (5) cognitive training.
Study NCT05006833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Interactive Text Message - Bundled Approach
Description: Text messages sent to parents will focus on receiving all three adolescent vaccines.
Study NCT05006833 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Interactive Text Message - Benefits Approach
Description: Text message will state that the HPV vaccine prevents cancer, is safe and effective, and is recommended for 11- to 12-year-olds.
Study NCT05213221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: 300mg, subcutaneous injection, q3w
Study NCT05213221 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: The first TACE will be started on d1, and the subsequent TACE will be performed on demand.
Study NCT05213221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 8mg,QD (body weight \<60kg); 12mg, QD (body weight ≥ 60kg)
Study NCT05277935 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Use of the WeCancer app combined with the smartwatch.
Description: To evaluate if a fitness tracker added to eHealth technology will improve quality of life compared to the use of eHealth technology alone in metastasis breast cancer patients treated with palbociclib and endocrine therapy
Study NCT06511648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib monotherapy
Description: Patients will receive treatment with erdafitinib alone (cohort 1)
Study NCT06511648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrelimab and Erdafitinib combination
Description: Patients will receive treatment neoadjuvant with erdafitinib plus cetrelimab intravenously (IV).(cohort 2)
Study NCT05126953 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: samfilcon A Lenses with EPG01 Packaging Solution
Description: samfilcon A Lenses with EPG01 Packaging Solution
Study NCT05126953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B+L Ultra Lenses
Description: Commercially available Biotrue ONEday lenses
Study NCT05895071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5%potassium hydroxide
Description: . In group-A 30 patients were given topical 5% potassium hydroxide solution on affected area once at night for upto 4 weeks
Study NCT05895071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liquid nitrogen
Description: in group-B 30 patients treated with cotton bud method of cryotherapy with liquid nitrogen once every two weeks. Patients were reassessed at every two weeks. The treatment carried out upto 12 weeks or until complete recovery from warts.
Study NCT04697316 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: To stimulate the left DLPFC, the anode electrode will be placed over F3 and the cathode will be placed over F4. Each stimulation will be applied for 20 min at 2mA intensity.
Study NCT04697316 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: For the sham treatment, stimulation will be stopped after 30 seconds. Current will be renewed five times throughout the session for 2 seconds each time, to mimic the tDCS stimulation.
Study NCT05546918 — intervention group
Intervention type: OTHER
Intervention: survey, interviews and focus groups
Description: The 2 groups of participants will be invited to:~* complete an anonymous online survey~* participate in individual semi-structured interviews and 2 focus groups
Study NCT04953299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Imagery training
Description: Behavioural intervention focused upon motivation and reaching achievable goals.
Study NCT04953299 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NHS 12 week weight loss programme
Description: The plan is designed to help individuals lose weight at a safe rate of 0.5kg to 1kg (1lb to 2lb) each week by sticking to a daily calorie allowance and introducing exercise.
Study NCT05142657 — intervention group
Intervention type: OTHER
Intervention: diet survey
Description: Dietary survey applied to all participants
Study NCT05828134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protein-enriched soup
Description: The participants in experimental group have a protein-enriched soup a day and do exercise a week
Study NCT06161701 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT06120660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music Therapy
Study NCT05960422 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Popliteal Sciatic Nerve Block
Description: Patients undergoing popliteal sciatic block, the side where the procedure would be performed in the prone position was sterilized after appropriate antisepsis. After visualizing the popliteal artery in the popliteal fossa with the probe it was advanced proximally in a horizontal and minimally lateral position to determine the point of separation of the tibial and peroneal nerves from the sciatic nerve. Subcutaneous local anesthesia was applied at this point after the skin, and the stimulator needle was advanced towards the sciatic nerve in an in-plane approach, passing through the skin and subcutaneous tissue, and then the nerve stimulator was opened up to 1 mA. After observing motor movement in the foot, the stimulator was reduced to 0.3-0.5 mA, and after observing motor movements for duration of 0.1 ms, 10 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine were administered to the target tissue
Study NCT05960422 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor canal block
Description: Patients in the group undergoing popliteal sciatic block + adductor canal block, with the extremity to be blocked slightly externally rotated, the anterior part of the thigh was prepared with the necessary antiseptic procedures while the patient was in the supine position. Using an ultrasound probe, the femoral artery was visualized by advancing the ultrasound probe distally, and the saphenous nerve was identified just lateral to the femoral artery, beneath the sartorius muscle. At the junction of the sartorius muscle and vastus medialis, 10 ml of 0.5% bupivacaine + 10 ml of 2% prilocaine were applied to the periphery of the saphenous nerve. Subsequently, the patient was turned prone, and a popliteal sciatic block was performed.
Study NCT04846439 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T infusion
Description: Sequential infusion of CD19 and BCMA autologous chimeric antigen receptor T cells, the infusion dose was determined according to the body weight of the subject and the effective content of cell preparation.
Study NCT04740346 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed tomography, Chest X-ray, and blood test
Description: CT will be performed every 3 months after gastrectomy in the 3-months follow-up group. CT will be performed every 6 months after gastrectomy in the 6 months follow-up group.
Study NCT05179850 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radiomic Algorithm
Description: Different radiomic, machine learning, and deep learning strategies for radiomic features extraction, sorting features and model constriction.
Study NCT04740346 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Computed tomography, Chest X-ray, and blood test
Description: CT will be performed every 3 months after gastrectomy in the 3-months follow-up group. CT will be performed every 6 months after gastrectomy in the 6 months follow-up group.
Study NCT04458168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Purposeful app
Description: Patients will be asked to use the Purposeful app every day, which should take no longer than 5 minutes. The app includes three key components: Explore, Act and Reflect. The Explore section provides thematically organized resources that suggest discrete actions users can try out and potentially incorporate into their lives. The app uses machine learning to customize resources presented to the user. The Act section is where users place actions they'd like to keep track of or build into a habit. Finally, the Reflect section includes daily reflections where the patient answers open ended questions regarding their alignment with their best self qualities, their sense of purpose, and more. Depending on whether users choose to allow push notifications, they will be notified daily to complete morning, afternoon, and/or evening reflections.~Participants will complete questionnaires at enrollment and at 1, 3, and 6 months after enrollment.
Study NCT05795439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-fat, vegan diet
Description: The intervention diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Participants will also be guided to favor foods with a low glycemic index. Animal products and added oils will be excluded. The diet is designed to derive approximately 10% of energy from fat, approximately 10-15% of energy from protein, and the remainder from mostly complex carbohydrates. The diet will also provide approximately 40 g of fiber per day.
Study NCT06060522 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT, CBCT
Description: Under general anesthesia, a lingual envelope incision is performed to access and remove the displaced third molar tooth or root, and a mucoperiosteal flap is released from the retromolar trigone to the medial surface of the mandibular first premolar. By carefully retracting the lingual soft tissue, an envelope flap is raised on the lingual side from the second premolar to the anterior boundary of the ramus. This protected the lingual nerve from injury. With great caution, the lingual flap is reflected up to the submandibular area so that the tooth or root fragment will be identified. An extra-oral finger is used as support.Through blunt dissection, the loose tooth or root is located, grabbed using a pair of artery forceps, and extracted.~The flaps are sutured using 3-0 Vicryl sutures after the wound is irrigated with normal saline.
Study NCT05327322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glycemic load
Description: Participants will be provided food to meet GL prescription for the duration of the trial.
Study NCT05327322 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Glycemic load
Description: Participants will be provided food to meet GL prescription for the duration of the trial.
Study NCT05327322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calorie restriction
Description: Participants will be provided food to meet their prescribed daily calorie intake for the duration of the trial (weight stable in first 16 weeks, weight loss in second 16 weeks).
Study NCT05327322 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calorie restriction
Description: Participants will be provided food to meet their prescribed daily calorie intake for the duration of the trial (weight stable in first 16 weeks, weight loss in second 16 weeks).
Study NCT05327322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral support
Description: All participants will receive behavioral supports in the form of email, text, information pages and weekly calls from the study staff to maximize adherence.
Study NCT05327322 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral support
Description: All participants will receive behavioral supports in the form of email, text, information pages and weekly calls from the study staff to maximize adherence.
Study NCT05449080 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Karyotype
Description: Patients were subjected to karyotype to determine their genotype
Study NCT06454214 — intervention group
Intervention type: DEVICE
Intervention: Multi-photon microscopy
Description: To conduct 3D structural imaging on human breast tissues
Study NCT05938283 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable Cardioverter Defibrillator implant
Description: ICD implant to protect patients from life threatening ventricular tachycardia or ventricular fibrillation
Study NCT05772130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive family letter and genomic test report
Study NCT05772130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT05772130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT05772130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Contact
Description: Receive family letter and genomic test report with provider-mediated contact
Study NCT05772130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05772130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT06379620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hi-OxSR Sequential Rebreathing mask (oxygen concentrator)
Description: Subjects will self-administer oxygen gas at 1to 3LPM via a Hi-OxSR Sequential Rebreathing mask (oxygen concentrator), twice a day for 30 minutes with ventilation supplemented by the subject's rebreathed exhaled air. Total treatment is for 14 days
Study NCT05770180 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 variant vaccine (Sf9 cell)
Description: WSK-V102
Study NCT05770180 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant COVID-19 vaccine (CHO cell)
Description: control 1
Study NCT05770180 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant COVID-19 vaccine (Sf9 cell)
Description: control 2
Study NCT05596812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Care Pathway
Description: The New Care Pathway will include continuation of lifestyle and dietary modification, self-blood glucose monitoring, and routine prenatal care.
Study NCT05005754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: During the study period, subjects are instructed to take one capsule of probiotics daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
Study NCT05005754 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: During the study period, subjects are instructed to take one capsule of placebo control daily for a total of 3 months. Aside from the probiotic supplement, all participants are instructed to continue their normal routine and not make any changes to their habitual diet or exercise habits.
Study NCT05936281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genakumab for injection
Description: 150 mg/1ml/ vial
Study NCT05936281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 0.5 mg/table
Study NCT04965051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart (IDegAsp)
Description: To evaluate the efficacy and safety of the IDegAsp in T1DM
Study NCT04965051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basal insulin plus pre-prandial insulin
Description: To evaluate the efficacy and safety of basal insulin plus pre-prandial insulin in T1DM
Study NCT06640543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: Postnatal women with low back pain will be treated with kinesiotape, three times per week for 4 weeks
Study NCT06640543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release
Description: Postnatal women with low back pain will be treated with myofascial release for 25 minutes three times per week for 4 weeks
Study NCT04558281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active ropivacaine 0.3% erector spinae plane perineural administration
Description: Ropivacaine 0.3% administration via an erector spinae plane perineural catheter
Study NCT04558281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo erector spinae plane perineural administration
Description: Normal saline administration via an erector spinae plane perineural catheter
Study NCT06195683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab for 4.5mg/kg IV Q3W day 1,22,43,64
Study NCT05492110 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary sinus reducer
Description: The Neovasc coronary sinus reducer is an hourglass-shaped stainless steel device inserted percutaneously into the coronary sinus and currently indicated for the treatment of refractory angina.
Study NCT05492110 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-procedure
Description: Implantation procedure with no device implanted
Study NCT05492110 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Invasive coronary physiology
Description: Invasive coronary physiology assessment as part of REMEDY-MECH mechanistic substudy
Study NCT05492110 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Invasive coronary physiology
Description: Invasive coronary physiology assessment as part of REMEDY-MECH mechanistic substudy
Study NCT06218212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Renastart formula
Description: * Renastart formula is an artificial formula is made by Vitaflo USA, Nestle Health Science Company.~* Renastart formula preparation: Adding one level scoop of Renastart to 30 ml water.~* Renastart formula will be used with breast milk, standard infant formula, standard pediatric infant feed and/ or mixed with diet.~* Renastart formula dosage will be adjusted to be 1/4 Renastart and 3/4 breast milk, standard infant formula or standard pediatric infant daily caloric feed ratio.~* Readjusting dosage ratio according to serum electrolytes levels especially potassium.
Study NCT06218212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcium carbonate (phosphorus binder) with / or sodium polystyrene sulfonate (potassium binder) with dosage 0.5-1mg/kg/day orally.
Description: calcium carbonate (phosphorus binder) in dosage of 45-65 mg/kg/day orally with / or sodium polystyrene sulfonate (potassium binder) in dosage of 0.5-1mg/kg/day orally.
Study NCT04594148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight-shift training
Description: Weight-shift training will consist of a single session of 10x 2.5min of mediolateral weight-shifting in the VR Wasp Game. Including breaks, the session will approximately take 45min.
Study NCT06474806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-DOTA-AE105
Description: AE105 is a uPAR-specific peptide that is bound to the chelator DOTA, which in turn holds the diagnostic radionuclide copper-64 (64Cu), which can be detected upon decay by PET imaging.
Study NCT06514469 — intervention group
Intervention type: DRUG
Intervention: Sufentanil intravenous administration followed consultation of remote physician
Description: Intravenous administration of sufentanil to patients with acute injury by paramedics only after phone-call consultation of medical doctor.
Study NCT06514469 — intervention group
Intervention type: DRUG
Intervention: Sufentanil intravenous administration based on paramedic competency
Description: Intravenous administration of sufentanil to patients with acute injury by paramedics based on their competencies
Study NCT05041192 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synaquell
Description: 7.9 grams of Synaquell are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).
Study NCT05041192 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7.9 grams of a placebo (that looks, smells, and tastes like Synaquell) are mixed with 10 ounces of water two times per day. The daily amount taken by each participant is (15.8 grams).
Study NCT05544370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive high intensity intervallic training group
Description: The intensive high intensity intervallic training group performs 6 sets of 60 seconds of work and 60 seconds of rest. During the first two weeks we work at an intensity of 80-85% of the reserve heart rate during the work phase and 50-55% of the reserve heart rate during the rest time. In weeks 3 and 4 the intensity in the work phase is increased by 5%, reaching from the fifth week onwards a work intensity of 95-95% of the reserve heart rate. The program duration is 8 weeks and the frequency of intervention is 2 sessions per week.